S16 Ep20: Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD
In today’s episode, we spoke with Eric K. Singhi, MD. Dr Singhi is an assistant professor in the departments of general oncology and thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.
Antibody-drug conjugates (ADCs) are rapidly emerging as one of the most exciting therapeutic advances in lung cancer. In this episode, Singhi explored how TROP2-directed ADCs are beginning to reshape treatment strategies across both non–small cell and small cell lung cancer.
Singhi discussed where these agents currently fit within the treatment algorithm for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.